FDA accepts Regeneron filing to widen use of Eylea

|About: Regeneron Pharmaceuticals... (REGN)|By:, SA News Editor

The FDA has accepted Regeneron's (REGN +3.3%) application to expand the use of its Eylea therapy to treat Macular Edema Following Branch Retinal Vein Occlusion, a common vascular disease among the elderly that is caused by a blockage of one of the small veins that carry blood away from the retina.

Regeneron's application follows a successful Phase III trial.

Eylea has already been authorized for other indications, including wet age-related macular edema.